Acetyl-DL-leucine (Tanganil™) in three patients with advanced multiple system atrophy
While ADLL improved RBD, it was poorly tolerated in these three patients with advanced-stage MSA of predominantly cerebellar type. Further studies are needed to evaluate its safety and efficacy in different, preferably early, stages of MSA.
Authors
- Annette Janzen (ORCID: https://orcid.org/0000-0001-8907-5831)
- Philipp T. Meyer (ORCID: https://orcid.org/0000-0001-8336-750X)
- Elisabeth Sittig
- Martin T. Henrich (ORCID: https://orcid.org/0000-0001-8295-4884)
- Fanni F. Geibl (ORCID: https://orcid.org/0000-0002-5480-0463)
- Michael Leo Strupp (ORCID: https://orcid.org/0000-0002-9544-2279)
- Élisabeth Ruppert (ORCID: https://orcid.org/0000-0002-0361-0985)
- Wolfgang H. Oertel
Institutions
- Philipps University of Marburg (DE)
- University Medical Center Freiburg (DE)
- LMU Klinikum (DE)
- Université de Strasbourg (FR)
- Ludwig-Maximilians-Universität München (DE)
Publication Details
- Journal
- BMC Neurology
- Published
- 2025-10-02
- DOI
- https://doi.org/10.1186/s12883-025-04451-7
- Citations
- 1
- Primary Topic
- Parkinson's Disease Mechanisms and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.39